Returning to HIV Care

CE / CME

Returning to HIV Care: Ensuring Services Are Inclusive and Equitable

Nurses: 0.75 Nursing contact hour

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: July 24, 2024

Expiration: July 23, 2025

Jason Halperin
Jason Halperin, MD, MPH, FIDSA

Activity

Progress
1 2
Course Completed

References

  1. UNAIDS. Understanding fast-track. Accelerating action to end the AIDS epidemic by 2030. unaids.org/sites/default/files/media_asset/201506_JC2743_Understanding_FastTrack_en.pdf. Accessed July 16, 2024.
  2. Centers for Disease Control and Prevention. HV surveillance supplemental report: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 territories and freely associated states, 2022. stacks.cdc.gov/view/cdc/156511. Accessed July 16, 2024.
  3. Camlin. Patient-reported factors associated with reengagement among HIV-infected patients disengaged from care in East Africa. AIDS. 2016;30:495.
  4. Centers for Disease Control and Prevention. HIV surveillance supplemental report 2021. HIV and AIDS data through December 2019 provided for the Ryan White HIV/AIDS Program, for fiscal year 2021. npin.cdc.gov/publication/hiv-surveillance-supplemental-report-2021-hiv-and-aids-data-through-december-2019. Accessed July 16, 2024.
  5. Dombrowski JC, Simoni JM, Katz DA, et al. Barriers to HIV care and treatment among participants in a public health HIV care relinkage program. AIDS Patient Care STDS. 2015;29:279. ​
  6. Giordano TP. Retention in HIV care: What the clinician needs to know Top Antivir Med. 2011;19:12.
  7. Mayer KH. Clin Infect Dis. Introduction: Linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. 2011;52(suppl 2):S205. ​
  8. HIV.gov. National HIV/AIDS strategy (2022-2025). hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025. Accessed July 16, 2024.
  9. Dombrowski JC, Ramchandani M, Golden MR. Implementation of low-barrier human immunodeficiency virus care: Lessons learned from the Max Clinic in Seattle. Clin Infect Dis. 2023;77:252
  10. Halperin. Personal Communication. Data on file.
  11. Onujiogu C, Brown J. Rapid ReSTART: Building on a rapid start model to expand access to ART in Louisiana. targethiv.org/sites/default/files/RWNC2020/15894Onujiogu.pdf. Accessed July 16, 2024.
  12. Rana AI. Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359. Presented at: CROI 2024. Abstr 212
  13. Hickey MD, Grochowski J, Mayorga-Munoz F, et al. 24-week viral suppression in patients starting long-acting CAB/RPV without HIV viral suppression. Presented at: CROI 2024. Abstr 628.
  14. Gandhi M, Hickey M, Imbert E, et al. Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV. Ann Intern Med. 2023;176:969.
  15. Hickey. Identifying implementation determinants and strategies for long-acting injectable cabotegravir-rilpivirine in people with HIV who are virally unsuppressed J Acquir Immune Defic Syndr. 2024;96:280.
  16. Sax PE, Thompson MA, Saag M, et al. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel. JAMA. 2024;331:1060.​